Beyond Air Inc Dossier
Qualitative Analysis
Business overview
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors. The company's core innovation is its proprietary LungFit platform, a cylinder-free, phasic flow generator and delivery system that produces NO on-demand from ambient air, eliminating the need for traditional high-pressure gas cylinders. Its first FDA-approved and CE-marked product, LungFit PH, is commercialized in the United States for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air operates primarily in the United States and has expanded its international distribution network to cover dozens of countries. The company also operates through its majority-owned oncology affiliate, Beyond Cancer, Ltd., and its NeuroNOS segment.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial footprint of the LungFit PH system globally through strategic distribution agreements. The company has established coverage in 40 countries, representing a combined population of over three billion people, with recent agreements signed in Germany, Brazil, Austria, Canada, the Netherlands, and Sri Lanka.
Expected impact: Drives sustained double-digit sequential revenue growth and reduces reliance on the U.S. market alone.
Implementing comprehensive cost-saving measures across R&D, SG&A, and the supply chain. Total operating expenses for the fiscal third quarter of 2026 were reduced by 36% year-over-year to approximately $6.9 million.
Expected impact: Significantly narrows operating losses and extends the cash runway into calendar year 2027.
Securing adoption of the LungFit PH system within the U.S. Department of Veterans Affairs (VA) healthcare network. The company completed its first sale of LungFit PH systems to a VA Medical Center during the fiscal third quarter of 2026.
Expected impact: Establishes a pathway for broader adoption across the largest integrated healthcare system in the United States.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Serves as the exclusive distributor of LungFit PH in the Asia-Pacific region, providing access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore, and Vietnam.
Terms: Triggered a $1.0 million milestone payment to Beyond Air in the fiscal fourth quarter of 2025 following CE Mark approval.
Provides Beyond Air's cylinder-free LungFit PH system access to Premier's alliance of approximately 4,350 member hospitals and health systems across the United States.
Terms: Standard GPO purchasing terms